

**Table 1: Clinical trials of Transplantation**

Study ID	Trial title [location]	Phase	Intervention	Study Start and estimated complete date	Condition [estimated enrolment]	Specificity	Doses
NCT 01634217	Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation [United States, Minnesota]	I	iTregs	Nov 2013 to Aug 2017	Non-myeloablative HLA-identical sibling donor PBSC Tx [n = 16]	Non-antigen specificity	3, 30, 300, and 1000×10 <sup>6</sup> /kg
NCT 01660607	Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell [United States, California]	I/II	Fresh nTregs	Dec 2011 to March 2018	Acute GVHD prevention [n = 54]	Non-antigen specificity	1.0×10 <sup>6</sup> /kg (Initial dose)
NCT 01795573	Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease (GVHD) [United States, Florida]	I	Donor alloantigen-reactive Treg (arTreg)	June 2014 to Jun 2019	Acute GVHD prevention [n = 48]	Alloantigen specificity	—
NCT 01903473	Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease [Belgium, Leuven and Liège]	II	Donor Treg	Jul 2013 to Dec 2016	Steroid -refractory chronic GVHD [n = 35]	Non-antigen specificity	0.5×10 <sup>6</sup> /kg
NCT 01911039	Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD [United States, California]	I	Fresh nTregs (donor Treg)	Jul 2013 to Jul 2016	Steroid-dependent/refractory chronic GVHD [n = 20]	Non-antigen specificity	1, 5, and 15 ×10 <sup>5</sup> /kg
NCT 01937468	Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD [United States, massachusetts]	I	Fresh nTregs and IL-2	Nov 2013 to Nov 2020	Steroid -refractory chronic GVHD [n = 25]	Non-antigen specificity	—
NCT 02385019	A Phase 1/2 Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic GVHD (TREGeneration) [Portugal, Lisboa and Porto]	I/II	Fresh nTregs (donor Treg)	Mar 2015 to Dec 2019	Steroid -refractory chronic GVHD [n = 22]	Non-antigen specificity	0.5, 1, 2, and 3×10 <sup>6</sup> /kg
NCT 02519816	Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid-refractory or Dependent Chronic GVHD (CARE) [Canada, Quebec]	II	Polyclonal nTregs	Mar 2016 to Aug 2017	Steroid-dependent/refractory chronic GVHD [n = 25]	Non-antigen specificity	—
NCT 02749084	Multiple Donor Treg DLI for Severe Refractory Chronic GVHD (TREG2015001) [Italy, Bologna]	I/II	Fresh nTregs (donor Treg)	Aug 2016 to Mar 2022	Refractory chronic GVHD [n = 20]	Non-antigen specificity	0.5, 1.0, and 2.0×10 <sup>6</sup> /kg
NCT 02991898	Treg Cell With IL-2 to Suppress aGVHD After Umbilical Cord Blood Transplantation [United States, Minnesota]	II	Fresh nTregs and IL-2	Feb 2017 to Jan 2025	Acute GVHD prevention [n = 10]	Non-antigen specificity	—

NCT 01624077	Safety Study of Using Regulatory T Cells Induce Liver Transplantation Tolerance (Treg) [China, Jiangsu]	I	iTregs	Dec 2014 to Dec 2015	Liver Tx [n = 1]	Alloantigen specificity	1×10 <sup>6</sup> /kg
NCT 02088931	Treg Adoptive Therapy for Subclinical Inflammation in Kidney Transplantation (TASK) [United States, California]	I	Polyclonal nTregs	Mar 2014 to Dec 2016	Living donor kidney Tx [n = 3]	Non-antigen specificity	320×10 <sup>6</sup> /total
NCT 02091232	Infusion of T-Regulatory Cells in Kidney Transplant Recipients (The ONE Study) [United States, Massachusetts]	I	Belatacept-induced nTregs	May 2014 to May 2018	Living donor kidney Tx [n = 8]	Non-antigen specificity	—
NCT 02129881	ONE Study UK Treg Trial (ONETreg1) [United Kingdom, London and Oxford]	I/II	Polyclonal nTregs	Apr 2014 to March 2017	Living donor kidney Tx [n = 12]	Non-antigen specificity	1-10×10 <sup>6</sup> /kg
NCT 02145325	Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant Recipients (TRACT) [United States, Illinois]	I	Polyclonal nTregs	Apr 2014 to Dec 2021	Living donor kidney Tx [n = 10]	Non-antigen specificity	—
NCT 02166177	Safety and Efficacy Study of Regulatory T Cell Therapy in Liver Transplant Patients (ThRIL) [United Kingdom, London]	I/II	Polyclonal nTregs	Jun 2014 to Jun 2019	Liver Tx [n = 26]	Non-antigen specificity	1 and 4.5×10 <sup>6</sup> /total
NCT 02188719	Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation (deLTa) [United States, California and Minnesota]	I	Donor arTreg	Dec 2014 to Jan 2022	Liver Tx [n = 24]	Alloantigen specificity	50, 200, and 800×10 <sup>6</sup> /total
NCT 02244801	Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Renal Transplantation (The ONE Study ) (DART) [United States, California]	I	Donor arTreg	Nov 2014 to Jun 2018	Living donor kidney Tx [n = 16]	Alloantigen specificity	300 and 900×10 <sup>6</sup> /total
NCT 02371434	The ONE Study nTreg Trial (ONEnTreg13) [Germany, Berlin]	I/II	Polyclonal nTregs	Jan 2015 to Dec 2017	Living donor kidney Tx [n = 9]	Non-antigen specificity	0.5, 1.0 and 3.0×10 <sup>6</sup> /kg
NCT 02474199	Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction (ARTEMIS) [United States, California, Illinois, and Minnesota]	I/II	Donor arTreg	Sep 2015 to Dec 2018	Liver Tx [n = 18] (Immunosuppression reduction)	Alloantigen specificity	400×10 <sup>6</sup> /total
NCT 02711826	Treg Therapy in Subclinical Inflammation in Kidney Transplantation (TASK) [United States, California]	I/II	I: Polyclonal nTregs II: Donor arTreg	Mar 2014 to Dec 2016	Subclinical inflammation in kidney Tx [n = 3]	Alloantigen specificity	320×10 <sup>6</sup> /total
UMIN 000015789	Tolerance induction by a regulatory T cell-based cell therapy in living donor liver transplantation [Japan, Hokkaido]	I/II	Donor arTreg (iTreg)	Nov 2012 to -	Living donor liver Tx [n = 40]	Alloantigen specificity	1.3-5.4×10 <sup>6</sup> /kg